Real-world evaluation of interstitial lung disease/pneumonitis in patients treated with trastuzumab deruxtecan for HER2-positive advanced or recurrent gastric cancer: a postmarketing surveillance study in Japan
The incidence of ILD with T-DXd in the real-world setting was similar to that observed in clinical trials, indicating no new ILD-related safety signals. Further investigation of the identified factors may offer insights into ILD incidence in high-risk populations.
Authors
- Hisato Kawakami (ORCID: https://orcid.org/0000-0002-3280-4850)
- Wataru Hashimoto (ORCID: https://orcid.org/0009-0007-3682-502X)
- Koji Uchino (ORCID: https://orcid.org/0000-0001-9970-0565)
- Kei Muro (ORCID: https://orcid.org/0000-0002-5572-743X)
Institutions
- Daiichi Sankyo (Germany) (DE)
- Tohoku University (JP)
- Daiichi-Sankyo (Japan) (JP)
- Aichi Cancer Center (JP)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105914
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Daiichi Sankyo Europe